SpyGlass Pharma brings together engineers, scientists and clinicians to develop life-changing therapies for patients suffering from various ophthalmic diseases. This team has the experience and expertise to bring these technologies from the lab to patients, so they can enjoy the benefits.
Chief Executive Officer
Patrick Mooney is a seasoned leader in ophthalmology, having led several launches and commercialization efforts of ophthalmic pharmaceuticals and medical devices. Most recently, he was Vice President and Head of the Ophthalmology Franchise at Novartis where he was responsible for the overall strategy and growth
Chief Executive Officer
Patrick Mooney is a seasoned leader in ophthalmology, having led several launches and commercialization efforts of ophthalmic pharmaceuticals and medical devices. Most recently, he was Vice President and Head of the Ophthalmology Franchise at Novartis where he was responsible for the overall strategy and growth of U.S. Ophthalmic Pharmaceuticals. Prior to Novartis, he led sales for Galderma’s Self Medication business unit and was with Alcon for 16 years, holding leadership positions of increasing responsibility in sales, marketing and operations in the United States and Asia. Patrick’s leadership experience in eye care spans the surgical, vision-care and pharmaceutical spectrum, and includes product launches in Retina, Glaucoma, Dry Eye as well as medical devices Patrick is highly regarded across the industry for his deep insight in the eye care marketplace, his passion for developing and commercializing new products and therapies that improve the lives of patients, and for his focus on developing people, and creating a strong team culture that yields successful business outcomes.
Co-founder, President and
Executive Chair of the Board
Dr. Kahook is a practicing ophthalmologist and serial entrepreneur with 15 years of startup and academic experience in research and development. Several of his devices are currently commercialized for clinical use. ClarVista Medical, acquired by Alcon in 2017, developed an advanced mo
Co-founder, President and
Executive Chair of the Board
Dr. Kahook is a practicing ophthalmologist and serial entrepreneur with 15 years of startup and academic experience in research and development. Several of his devices are currently commercialized for clinical use. ClarVista Medical, acquired by Alcon in 2017, developed an advanced modular intraocular lens system co-invented by Dr. Kahook. He is the inventor of the Kahook Dual Blade, which is marketed globally by New World Medical. Dr. Kahook also has extensive experience in intraocular lens material innovation and novel ophthalmic drug delivery methods. His inventions have been the focus of over $150 million in venture backed funding and industry led development and commercialization since 2008 and his devices have been used to treat 100s of thousands of patients globally.
Co-founder and Chief Technology Officer
Glenn Sussman is a serial inventor and entrepreneur with 30+ years of experience in the ophthalmic space. Prior to co-founding SpyGlass, he was responsible for the development of a novel IOL for ClarVista Medical which was acquired by Alcon in 2017. Glenn previously served in an R&D leadership role
Co-founder and Chief Technology Officer
Glenn Sussman is a serial inventor and entrepreneur with 30+ years of experience in the ophthalmic space. Prior to co-founding SpyGlass, he was responsible for the development of a novel IOL for ClarVista Medical which was acquired by Alcon in 2017. Glenn previously served in an R&D leadership role at Alcon for 18 years. He has supported and led development for several other industry leaders and academic facilities. Glenn has over 60 issued US patents in areas that range from intraocular lenses to surgical devices for ophthalmic surgery.
Chief Operating Officer
James Dennewill brings over 20 years of medical device industry experience, specializing in the development of products, people and processes required to bring new technologies to market. Prior to SpyGlass, he spent over six years with Cianna Medical (acquired by Merit Medical), where he held various positions of e
Chief Operating Officer
James Dennewill brings over 20 years of medical device industry experience, specializing in the development of products, people and processes required to bring new technologies to market. Prior to SpyGlass, he spent over six years with Cianna Medical (acquired by Merit Medical), where he held various positions of escalating responsibility including VP of Operations and COO. James also spent over 10 years with Med-Logics, Inc., where he managed the development of ophthalmic products, resulting in a range of U.S. and international patents, and served as Management Representative for all regulatory affairs.
SpyGlass Pharma is excited to announce Patrick Mooney has joined our team as Chief Executive Officer. He has been a leader in our industry for years with high level positions in Alcon and Novartis and is the perfect fit for the team we have assembled to address chronic ophthalmic diseases. Co-Founder Glenn Sussman has been appointed Chief Technology Officer and will continue to lead the SpyGlass' development efforts. (View full press release)
SpyGlass Pharma introduces a new name, which captures the essence of the company’s focus on delivering improved pharmaceutical therapies for ophthalmic diseases. SpyGlass Pharma is the second company formed from the SpyGlass Ophthalmics incubator. In conjunction with this name change, the company is relocating to new headquarters in Aliso Viejo, CA.
SpyGlass Ophthalmics (SGO), a privately-held ophthalmic therapeutics company announced that it has secured $27.5 million in Series B financing. The financing, which was led by Vensana Capital alongside existing investor New Enterprise Associates (NEA), will enable the company to further advance development efforts of platform technology that has the potential to address several unmet needs across a range of chronic ophthalmic diseases. (View full press release)
SpyGlass Ophthalmics (SGO) has partnered with New Enterprise Associates (NEA) to support the development of novel technologies with a vision towards a higher quality of life. The funding will be used to achieve SGO’s research, development and clinical targets.
Copyright © 2022 SpyGlass Pharma - All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.